Allergist · Mayo Clinic · United States (US) · Immunology
Data minimisation
Cadence target for Tier 2: 2 per year (assumption)
1 of 1 expected engagements
No insights captured from engagements with this stakeholder.
All engagements including drafts, newest first
31 Aug 2026
Adolescent population, Phase IIb efficacy
05 Jan 2026
Phase IIb efficacy, Long-term safety monitoring
Mayo Clinic
Thoracic medical oncologist
Community nephrologist